Literature DB >> 12801388

Pathology and pathways of Alzheimer's disease with an update on new developments in treatment.

Steven T DeKosky1.   

Abstract

As our understanding of the complex pathology of Alzheimer's disease improves, more targets for therapy emerge. These include the actions of beta amyloid, the inflammatory cascade, pathobiology of tau proteins' conversion to neurofibrillary tangles, oxidative neuronal damage, and neurotransmitter depletion. Many agents now under investigation target the early stages of the disease process, aiming to prevent or slow the development of symptoms. This article reviews the current understanding of the course and pathology of Alzheimer's disease as it relates to emerging therapies, then summarizes some promising current research directions in primary prevention, secondary prevention, and treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12801388     DOI: 10.1046/j.1532-5415.5157.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  10 in total

1.  [Statement to the preliminary report of the IQWiG A05-19B ginkgo-containing preparation at Alzheimers dementia].

Authors:  Manfred Gogol; Dieter Lüttje; Cornel Sieber; Hansjörg Werner
Journal:  Z Gerontol Geriatr       Date:  2007-08       Impact factor: 1.281

Review 2.  The Alzheimer's disease neuroimaging initiative.

Authors:  Susanne G Mueller; Michael W Weiner; Leon J Thal; Ronald C Petersen; Clifford Jack; William Jagust; John Q Trojanowski; Arthur W Toga; Laurel Beckett
Journal:  Neuroimaging Clin N Am       Date:  2005-11       Impact factor: 2.264

3.  Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI).

Authors:  Susanne G Mueller; Michael W Weiner; Leon J Thal; Ronald C Petersen; Clifford R Jack; William Jagust; John Q Trojanowski; Arthur W Toga; Laurel Beckett
Journal:  Alzheimers Dement       Date:  2005-07       Impact factor: 21.566

4.  Differential effects of two hexahydropyrroloindole carbamate-based anticholinesterase drugs on the amyloid beta protein pathway involved in Alzheimer's disease.

Authors:  Debomoy K Lahiri; George M Alley; David Tweedie; Demao Chen; Nigel H Greig
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

5.  Ribosome dysfunction is an early event in Alzheimer's disease.

Authors:  Qunxing Ding; William R Markesbery; Qinghua Chen; Feng Li; Jeffrey N Keller
Journal:  J Neurosci       Date:  2005-10-05       Impact factor: 6.709

6.  Design and Synthesis of New Dual Binding Site Cholinesterase Inhibitors: in vitro Inhibition Studies with in silico Docking.

Authors:  Muhammad Yar; Marek Bajda; Rana Atif Mehmood; Lala Rukh Sidra; Nisar Ullah; Lubna Shahzadi; Muhammad Ashraf; Tayaba Ismail; Sohail Anjum Shahzad; Zulfiqar Ali Khan; Syed Ali Raza Naqvi; Nasir Mahmood
Journal:  Lett Drug Des Discov       Date:  2014-03       Impact factor: 1.150

7.  Phosphoinositide 3-kinase inhibitor AS605240 ameliorates streptozotocin-induced Alzheimer's disease like sporadic dementia in experimental rats.

Authors:  Ramesh Alluri; Sivamallikarjuna Reddy Ambati; Kasiviswanth Routhu; Spandana Rajendra Kopalli; Sushruta Koppula
Journal:  EXCLI J       Date:  2020-01-06       Impact factor: 4.068

8.  Potential of chromatin modifying compounds for the treatment of Alzheimer's disease.

Authors:  Tom C Karagiannis; Katherine Ververis
Journal:  Pathobiol Aging Age Relat Dis       Date:  2012-02-20

Review 9.  Proximate Mediators of Microvascular Dysfunction at the Blood-Brain Barrier: Neuroinflammatory Pathways to Neurodegeneration.

Authors:  Barry W Festoff; Ravi K Sajja; Luca Cucullo
Journal:  Biomed Res Int       Date:  2017-08-14       Impact factor: 3.411

10.  Design, Synthesis of N-phenethyl Cinnamide Derivatives and Their Biological Activities for the Treatment of Alzheimer's Disease: Antioxidant, Beta-amyloid Disaggregating and Rescue Effects on Memory Loss.

Authors:  Tian Chai; Xiao-Bo Zhao; Wei-Feng Wang; Yin Qiang; Xiao-Yun Zhang; Jun-Li Yang
Journal:  Molecules       Date:  2018-10-16       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.